about
Alternating hemiplegia of childhood-related neural and behavioural phenotypes in Na+,K+-ATPase α3 missense mutant mice.Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's diseaseRandomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.Wilson disease: Canadian perspectives on presentation and outcomes from an adult ambulatory setting.Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.New treatments for the motor symptoms of Parkinson's disease.Clinical spectrum of levodopa-induced complications.The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome.Monoamine reuptake inhibitors in Parkinson's disease.Measuring mild cognitive impairment in patients with Parkinson's diseaseReproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.Advances in the delivery of treatments for Parkinson's disease.Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.Development of the Comprehensive Cervical Dystonia Rating Scale: MethodologyClinimetric testing of the comprehensive cervical dystonia rating scale.Medication-related impulse control and repetitive behaviors in Parkinson disease.Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.Levodopa-related motor complications--phenomenology.Non-dopaminergic treatments in development for Parkinson's disease.Psychiatric comorbidities in dystonia: emerging concepts.Overview of the extranigral aspects of Parkinson disease.Serotonin and Parkinson's disease: On movement, mood, and madness.The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?The serotonergic system in Parkinson's disease.l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale.Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials.Drug treatments for the neuropsychiatric complications of Parkinson's disease.The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.Non-dopaminergic treatments for motor control in Parkinson's disease.Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.Emerging drugs for levodopa-induced dyskinesia.Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates.Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
P50
Q27331805-910D5821-44F0-4D15-BFBC-10731C9923B6Q30249553-33CDF925-CBAF-4F9D-9FAA-85E2F7BE19D9Q33607256-6DE68BA8-67C8-4DFA-9465-41C463BD7833Q34113369-A947B328-91E2-4A7E-9F12-FA7D7086749DQ34312473-5892AEE2-220C-46C0-9526-7FAB3416E373Q34388686-8C8CFCAF-67DA-4E82-A0D3-1BF1706DD173Q34443682-6DE73E60-BB11-4A9D-9B96-CCEB82AFE36CQ34452721-8A843589-0785-4C31-ABF5-7753985CD6F8Q34817812-960181D8-1AF9-4E46-A212-662AFBF1237CQ34821410-977D1CF0-D927-43B5-A894-B2B3F56C9398Q35165280-E3B3B471-53C3-483B-BEE8-764AA2EFC7FCQ35914968-809E58CB-9AB9-48FE-9112-4C4805243EDDQ36071428-EB9B4859-E6A0-4886-ABF0-3F144CF38DB8Q36316936-F5F871D6-998D-4B3D-8C78-49693E23ECB1Q36549794-755709E5-A502-41C6-B7CC-90BFE03E8AC2Q36785510-6EC352BD-B98F-4609-885C-A678D6C917F5Q36803313-D036B537-045A-4578-AE2C-7EF71DBE5A1CQ36910122-FF99111D-866D-408A-9E72-3AAEEE5B89CBQ37260951-86E95480-D68E-4B6E-A913-4D18A5F2C60AQ37264469-1D3F44D7-CDB5-481D-9A09-FF5CAF37D332Q37291597-8C7FB493-95AB-4762-A892-F5363F7CE985Q37346782-C503C6AE-FFB8-4965-88A7-4DC1F512FBC8Q37388931-B8152C15-FF13-4AC5-9FA8-87C5C74BCA47Q37468874-D0E17CC1-2511-4DD2-A672-A74A5EC73372Q37796015-0370B1CC-8A84-4AD2-86FD-39E3087A258DQ37904514-E0656642-97F6-48F4-A65C-7884E04A50C0Q37924025-66202889-3D0C-42B1-9684-B4A3CE44B3B1Q37930020-E8C100A2-924B-447B-8156-833A81AF38A0Q37948713-710CB063-8961-4174-9139-831C82A2241EQ38039066-90AF664A-493A-4222-9790-BB71883C33ACQ38043416-4193E3B1-46F5-4C82-A6BD-8F4973495055Q38066123-01EB4C23-3BD2-4163-B115-A408597300A5Q38067142-E0281791-5173-4197-A4B6-B06947B9A261Q38074141-42002652-68BC-4D98-B5EB-CB91203A4207Q38081485-A679CB96-A39B-479C-86F5-28934E45132EQ38126817-75040840-54E1-4323-BF04-69B3BEA059F1Q38222076-173DBCC6-8BCC-48A2-86D6-4C55EC5FE309Q38242091-F9E191DB-DBB5-4D84-A497-4CC93C7C1F8BQ38243417-DCEF64AC-49B4-40DD-848D-55F218CE0399Q38383616-0DED2064-0F11-4CB3-8099-CC4BFC971E10
P50
name
Susan H Fox
@ast
Susan H Fox
@en
Susan H Fox
@nl
type
label
Susan H Fox
@ast
Susan H Fox
@en
Susan H Fox
@nl
prefLabel
Susan H Fox
@ast
Susan H Fox
@en
Susan H Fox
@nl
P214
P214
P31
P734
P7859
lccn-n2013180367